CN1229334C - α4介导的细胞粘附的抑制剂 - Google Patents

α4介导的细胞粘附的抑制剂 Download PDF

Info

Publication number
CN1229334C
CN1229334C CNB018149871A CN01814987A CN1229334C CN 1229334 C CN1229334 C CN 1229334C CN B018149871 A CNB018149871 A CN B018149871A CN 01814987 A CN01814987 A CN 01814987A CN 1229334 C CN1229334 C CN 1229334C
Authority
CN
China
Prior art keywords
compound
group
dimethoxy
phenylalanine
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018149871A
Other languages
English (en)
Chinese (zh)
Other versions
CN1449377A (zh
Inventor
筑本美喜子
野村纯宏
川口隆行
久米俊行
I·瑟卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of CN1449377A publication Critical patent/CN1449377A/zh
Application granted granted Critical
Publication of CN1229334C publication Critical patent/CN1229334C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
CNB018149871A 2000-08-31 2001-08-27 α4介导的细胞粘附的抑制剂 Expired - Fee Related CN1229334C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22912800P 2000-08-31 2000-08-31
US60/229,128 2000-08-31

Publications (2)

Publication Number Publication Date
CN1449377A CN1449377A (zh) 2003-10-15
CN1229334C true CN1229334C (zh) 2005-11-30

Family

ID=22859926

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018149871A Expired - Fee Related CN1229334C (zh) 2000-08-31 2001-08-27 α4介导的细胞粘附的抑制剂

Country Status (28)

Country Link
US (6) US7026501B2 (cg-RX-API-DMAC7.html)
EP (1) EP1315694B1 (cg-RX-API-DMAC7.html)
JP (1) JP3899022B2 (cg-RX-API-DMAC7.html)
KR (1) KR100528049B1 (cg-RX-API-DMAC7.html)
CN (1) CN1229334C (cg-RX-API-DMAC7.html)
AR (1) AR034556A1 (cg-RX-API-DMAC7.html)
AT (1) ATE292615T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001286778B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113629A (cg-RX-API-DMAC7.html)
CA (1) CA2418054C (cg-RX-API-DMAC7.html)
CZ (1) CZ303460B6 (cg-RX-API-DMAC7.html)
DE (1) DE60109943T2 (cg-RX-API-DMAC7.html)
DK (1) DK1315694T3 (cg-RX-API-DMAC7.html)
ES (1) ES2240509T3 (cg-RX-API-DMAC7.html)
HK (1) HK1052684B (cg-RX-API-DMAC7.html)
HU (1) HUP0302693A3 (cg-RX-API-DMAC7.html)
IL (2) IL154305A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001837A (cg-RX-API-DMAC7.html)
MY (1) MY129000A (cg-RX-API-DMAC7.html)
NO (1) NO327861B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ524043A (cg-RX-API-DMAC7.html)
PL (1) PL206656B1 (cg-RX-API-DMAC7.html)
PT (1) PT1315694E (cg-RX-API-DMAC7.html)
RU (1) RU2250895C2 (cg-RX-API-DMAC7.html)
SI (1) SI1315694T1 (cg-RX-API-DMAC7.html)
TW (1) TWI224587B (cg-RX-API-DMAC7.html)
WO (1) WO2002018320A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200301039B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302653B6 (cs) 2000-08-18 2011-08-17 Ajinomoto Co., Inc. Fenylalaninové deriváty, alfa-4-integrinový antagonist, terapeutické cinidlo nebo preventivní cinidlo a farmaceutický prostredek obsahující tyto deriváty
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
KR100881647B1 (ko) 2001-04-27 2009-02-04 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로[1,5-ａ]피리딘 화합물 및 그 의약
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
PT1555265E (pt) * 2002-10-22 2009-05-12 Eisai R&D Man Co Ltd Compostos de 7-fenil pirazolopiridina
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014534A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
EP1660439A2 (en) 2003-08-08 2006-05-31 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
ZA200605587B (en) 2003-12-22 2008-02-27 Ajinomoto Kk Novel phenylalanine derivative
US7410971B2 (en) 2003-12-26 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
JP4966017B2 (ja) 2004-12-20 2012-07-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 １−シクロプロピルメチル−４−［２−（３，３，５，５−テトラメチルシクロヘキシル）フェニル］ピペラジンの塩および結晶
JP2008542407A (ja) 2005-06-09 2008-11-27 ユセベ ファルマ ソシエテ アノニム ２，６キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用
EP2091916A2 (en) * 2005-11-23 2009-08-26 AstraZeneca AB L-phenylalanine derivatives and their use as integrin antagonists
EP1984344B1 (en) * 2005-12-29 2012-09-26 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7855291B2 (en) 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
WO2007092471A2 (en) * 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP1984330A1 (en) * 2006-02-09 2008-10-29 AstraZeneca AB Chemical compounds
EP2676967B1 (en) 2006-02-28 2019-08-14 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007100763A2 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
JP5504390B2 (ja) 2006-03-03 2014-05-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法
JP5553752B2 (ja) * 2007-08-24 2014-07-16 レクシコン ファーマシューティカルズ インコーポレイテッド ４−フェニル−６−（２，２，２−トリフルオロ−１−フェニルエトキシ）ピリミジン系化合物を調製する方法
ES2396126T3 (es) 2008-04-15 2013-02-19 Eisai R&D Management Co., Ltd. Compuesto de 3-fenilpirazol[5,1-b]tiazol
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
CA2777158A1 (en) 2009-10-21 2011-04-28 Joseph Paul Adams Process for preparing a phenylalanine derivative
SG181653A1 (en) 2010-01-11 2012-07-30 Biogen Idec Inc Assay for jc virus antibodies
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PT2715352T (pt) 2011-05-31 2019-06-12 Biogen Ma Inc Método de avaliação do risco de lmp
WO2013126595A1 (en) * 2012-02-21 2013-08-29 Massachusetts Eye And Ear Infirmary Methods for treating corneal and conjunctival inflammation and inflammatory disorders
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN119462635A (zh) 2018-10-30 2025-02-18 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
EP0728145A1 (en) 1993-11-01 1996-08-28 Ciba-Geigy Japan Limited Endothelin receptor antagonists
BR9507220A (pt) 1994-03-28 1997-09-09 Japat Ltd Antagonistas de receptores de endotelina
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
EP0821670A1 (en) 1995-04-21 1998-02-04 Novartis AG N-aroylamino acid amides as endothelin inhibitors
JP2002501537A (ja) 1997-05-29 2002-01-15 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのスルホンアミド類
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
ES2257808T3 (es) 1997-05-29 2006-08-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Acidos biarilalcanoicos como inhibidores de adhesion celular.
ATE256699T1 (de) 1997-05-30 2004-01-15 Celltech Therapeutics Ltd Entzündungshemmende tyrosin-derivate
WO1998058902A1 (en) 1997-06-23 1998-12-30 Tanabe Seiyaku Co., Ltd. INHIBITORS OF α4β1MEDIATED CELL ADHESION
AU8661298A (en) 1997-07-31 1999-02-22 American Home Products Corporation Dipeptide compounds which inhibit leukocyte adhesion mediated by VLA-4
CN1133648C (zh) 1997-07-31 2004-01-07 伊兰药品公司 抑制vla-4介导的白细胞粘附的取代的苯丙氨酸型化合物
KR20010022414A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제시키는4-아미노-페닐알라닌형 화합물
HUP0003921A3 (en) 1997-07-31 2001-03-28 Wyeth Corp Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
JP2001512135A (ja) 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Ｖｌａ−４によって媒介された白血球接着を阻害するジペプチドおよび関連化合物
IL133635A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
JP2001512136A (ja) 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Ｖｌａ−４により仲介される白血球接着を抑制する化合物
ATE260243T1 (de) 1997-08-22 2004-03-15 Hoffmann La Roche N-aroylphenylalaninderivate
AU739511B2 (en) * 1997-08-22 2001-10-11 F. Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
US6191171B1 (en) * 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
WO1999026922A1 (en) 1997-11-21 1999-06-03 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
JP2001524465A (ja) 1997-11-24 2001-12-04 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害剤としての置換β−アラニン誘導体
JP2001523711A (ja) 1997-11-24 2001-11-27 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害薬としての環状アミノ酸誘導体
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
WO1999064395A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
ES2220140T3 (es) 1998-12-22 2004-12-01 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion mediada de celulas por alfa 4 beta 1 (a4b1).
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
AU6903200A (en) * 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
AU6909300A (en) * 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1214292B1 (en) * 1999-09-24 2007-06-13 Genentech, Inc. Tyrosine derivatives
US20040198833A1 (en) 2000-08-31 2004-10-07 Bender David Michael Acetylenic sulfonamide derivatives

Also Published As

Publication number Publication date
US7026501B2 (en) 2006-04-11
WO2002018320A2 (en) 2002-03-07
DE60109943D1 (de) 2005-05-12
PL206656B1 (pl) 2010-09-30
US20100113820A1 (en) 2010-05-06
CA2418054A1 (en) 2002-03-07
JP2004507519A (ja) 2004-03-11
DE60109943T2 (de) 2006-02-09
CZ303460B6 (cs) 2012-09-26
PT1315694E (pt) 2005-07-29
KR20030059099A (ko) 2003-07-07
US7872151B2 (en) 2011-01-18
NO20030885L (no) 2003-02-25
MY129000A (en) 2007-03-30
NO327861B1 (no) 2009-10-05
SI1315694T1 (en) 2005-10-31
US7671090B2 (en) 2010-03-02
US20130289109A1 (en) 2013-10-31
EP1315694A2 (en) 2003-06-04
BR0113629A (pt) 2003-07-22
US20090111879A1 (en) 2009-04-30
NZ524043A (en) 2004-08-27
RU2250895C2 (ru) 2005-04-27
US20110077299A1 (en) 2011-03-31
AU8677801A (en) 2002-03-13
MXPA03001837A (es) 2003-10-15
AU2001286778B2 (en) 2005-02-10
HK1052684A1 (en) 2003-09-26
CN1449377A (zh) 2003-10-15
HUP0302693A3 (en) 2005-05-30
CZ2003487A3 (cs) 2003-06-18
WO2002018320A3 (en) 2002-06-06
EP1315694B1 (en) 2005-04-06
ZA200301039B (en) 2004-02-09
PL365668A1 (en) 2005-01-10
IL154305A (en) 2010-11-30
ES2240509T3 (es) 2005-10-16
ATE292615T1 (de) 2005-04-15
AR034556A1 (es) 2004-03-03
KR100528049B1 (ko) 2005-11-15
US7456217B2 (en) 2008-11-25
NO20030885D0 (no) 2003-02-25
JP3899022B2 (ja) 2007-03-28
CA2418054C (en) 2008-08-05
TWI224587B (en) 2004-12-01
HUP0302693A2 (hu) 2003-12-29
US20050282900A1 (en) 2005-12-22
HK1052684B (en) 2005-07-22
US8501809B2 (en) 2013-08-06
US20030176498A1 (en) 2003-09-18
DK1315694T3 (da) 2005-08-08
IL154305A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
CN1229334C (zh) α4介导的细胞粘附的抑制剂
CN1050605C (zh) 环烷并吲哚和环烷并氮杂吲哚衍生物,其制备方法和含有它们的药物组合物
CN1207056C (zh) 含肽的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
CN1179945C (zh) 吲哚衍生物、其制备方法及用途
CN1049651C (zh) 金属蛋白酶抑制剂
CN1022487C (zh) 制备新的药物化合物
CN1173945C (zh) 5-硫代-ω-取代的苯基-前列腺素E衍生物、其制备方法及含有它们作为活性成分的药物
CN1052227C (zh) 作为粘结受体拮抗剂的噁唑烷酮,其制备方法和含它们的药物组合物
CN1279900C (zh) 用于睡眠障碍的加巴喷丁类似物
CN1407972A (zh) 4－嘧啶基－n－酰基－l－苯基丙氨酸类化合物
CN1653046A (zh) 8－氮杂前列腺素衍生化合物以及包含该化合物作为活性成分的药物
CN1578767A (zh) 哌啶－2－酮衍生化合物及包含其作为活性成分的药学组合物
CN1020098C (zh) 硫代内酰胺-n-乙酸衍生物的生产
CN1196682C (zh) 4－吡啶基－n－酰基－l－苯丙氨酸
CN1073166A (zh) 羟肟酸衍生物
CN1832742A (zh) 用于治疗心血管疾病的血管紧张素ii受体阻断剂氯沙坦、缬沙坦、坎地沙坦、替米沙坦、依普罗沙坦和奥美沙坦的硝基氧基衍生物
CN1468216A (zh) 含氮五员环化合物
CN1330637A (zh) 用于治疗炎性疾病的化合物
CN1774244A (zh) 用于治疗代谢紊乱的化合物
CN1058019C (zh) 环状氨基酸衍生物
CN1132511A (zh) 基质金属蛋白酶抑制剂
CN1489582A (zh) 二氢化萘衍生物及包含该衍生物作为活性成分的药物
CN1198649C (zh) 用于治疗瘙痒的含pgd2受体拮抗剂的药物组合物
CN1074904A (zh) 苯并呋喃基-和噻吩基甲硫基-链烷羧酸衍生物
CN1867572A (zh) 蛋白酶体抑制剂及其使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051130

Termination date: 20150827

EXPY Termination of patent right or utility model